A randomized-withdrawal phase 3 study evaluating the safety and efficacy of CG5503 [tapentadol] extended release (ER) in subjects with painful diabetic peripheral neuropathy.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

01 Feb 2015 A pooled analysis results from NCT00455520 and NCT01041859 published in the Clinical Drug Investigation.
19 May 2012 Results presented at the 31st Annual Scientific Meeting of the American Pain Society.
20 Jan 2011 Primary endpoint 'Pain-intensity' has been met

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com